Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Felzartamab - MorphoSys

Drug Profile

Felzartamab - MorphoSys

Alternative Names: HIB-202; MOR 202; MOR-03087; TJ-202

Latest Information Update: 25 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys
  • Developer Human Immunology Biosciences; I-MAB Biopharma; MorphoSys
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Phagocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Membranous glomerulonephritis; Renal transplant rejection
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma

Highest Development Phases

  • Preregistration Multiple myeloma
  • Phase II IgA nephropathy; Membranous glomerulonephritis; Renal transplant rejection
  • Phase I Lupus nephritis; Systemic lupus erythematosus
  • No development reported Leukaemia
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 21 Mar 2024 Felzartamab - MorphoSys receives Orphan Drug status for Renal transplant rejection in USA
  • 04 Mar 2024 I-MAB Biopharma plans a phase-I trial (In volunteers) in China (IV) (NCT06285201),
  • 31 Oct 2023 Felzartamab - MorphoSys receives Breakthrough Therapy status for Membranous glomerulonephritis in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top